Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Receptors, Opioid, kappa | 41 | 2021 | 134 | 8.980 |
Why?
|
Nucleus Accumbens | 35 | 2021 | 360 | 5.570 |
Why?
|
Reward | 40 | 2023 | 980 | 3.750 |
Why?
|
Dynorphins | 13 | 2017 | 82 | 3.380 |
Why?
|
Cocaine | 32 | 2017 | 944 | 3.290 |
Why?
|
Fear | 23 | 2024 | 1496 | 2.780 |
Why?
|
Behavior, Animal | 36 | 2024 | 1865 | 2.750 |
Why?
|
Substance Withdrawal Syndrome | 14 | 2025 | 627 | 2.740 |
Why?
|
Cyclic AMP Response Element-Binding Protein | 19 | 2020 | 501 | 2.600 |
Why?
|
Narcotic Antagonists | 20 | 2021 | 591 | 2.380 |
Why?
|
Self Stimulation | 23 | 2021 | 46 | 2.340 |
Why?
|
Psychopharmacology | 4 | 2019 | 146 | 2.020 |
Why?
|
Pituitary Adenylate Cyclase-Activating Polypeptide | 7 | 2024 | 108 | 1.780 |
Why?
|
Rats, Sprague-Dawley | 71 | 2025 | 8108 | 1.760 |
Why?
|
Rats | 109 | 2025 | 23713 | 1.750 |
Why?
|
Extinction, Psychological | 10 | 2020 | 367 | 1.660 |
Why?
|
Tetrahydroisoquinolines | 7 | 2021 | 81 | 1.600 |
Why?
|
Receptors, Dopamine D1 | 6 | 2021 | 276 | 1.480 |
Why?
|
Morphine | 17 | 2016 | 658 | 1.470 |
Why?
|
Stress, Psychological | 15 | 2024 | 4526 | 1.470 |
Why?
|
Proto-Oncogene Proteins c-fos | 12 | 2016 | 582 | 1.410 |
Why?
|
Antidepressive Agents | 12 | 2019 | 2912 | 1.400 |
Why?
|
Corticotropin-Releasing Hormone | 10 | 2020 | 362 | 1.400 |
Why?
|
Conditioning, Operant | 19 | 2020 | 306 | 1.400 |
Why?
|
Amygdala | 19 | 2024 | 1375 | 1.390 |
Why?
|
Anti-Anxiety Agents | 6 | 2019 | 405 | 1.330 |
Why?
|
Ventral Tegmental Area | 13 | 2017 | 136 | 1.330 |
Why?
|
Receptors, AMPA | 12 | 2016 | 334 | 1.310 |
Why?
|
Morphine Dependence | 5 | 2016 | 27 | 1.280 |
Why?
|
Journal Impact Factor | 2 | 2021 | 157 | 1.240 |
Why?
|
Animals | 188 | 2025 | 168965 | 1.230 |
Why?
|
Attention | 9 | 2021 | 2413 | 1.210 |
Why?
|
Editorial Policies | 4 | 2019 | 458 | 1.170 |
Why?
|
Diterpenes, Clerodane | 14 | 2011 | 42 | 1.150 |
Why?
|
Bibliometrics | 3 | 2022 | 356 | 1.090 |
Why?
|
Septal Nuclei | 4 | 2024 | 82 | 1.090 |
Why?
|
Dopamine Uptake Inhibitors | 12 | 2017 | 286 | 1.070 |
Why?
|
Dizocilpine Maleate | 8 | 2009 | 171 | 1.060 |
Why?
|
Motor Activity | 30 | 2017 | 2713 | 1.060 |
Why?
|
Corpus Striatum | 9 | 2017 | 1217 | 1.020 |
Why?
|
Periodicals as Topic | 5 | 2020 | 1465 | 1.010 |
Why?
|
Peer Review, Research | 2 | 2019 | 343 | 1.010 |
Why?
|
Brain | 38 | 2023 | 27163 | 1.010 |
Why?
|
Medial Forebrain Bundle | 8 | 2021 | 42 | 1.000 |
Why?
|
Cues | 6 | 2020 | 877 | 1.000 |
Why?
|
Neurosciences | 2 | 2019 | 384 | 0.900 |
Why?
|
Central Nervous System Stimulants | 8 | 2024 | 1168 | 0.890 |
Why?
|
Piperidines | 7 | 2021 | 1667 | 0.890 |
Why?
|
Ketamine | 4 | 2015 | 527 | 0.880 |
Why?
|
Substance-Related Disorders | 15 | 2017 | 4422 | 0.870 |
Why?
|
Anxiety Disorders | 6 | 2017 | 2745 | 0.870 |
Why?
|
Naloxone | 8 | 2013 | 372 | 0.850 |
Why?
|
Dopamine | 12 | 2017 | 1581 | 0.840 |
Why?
|
Swimming | 10 | 2011 | 212 | 0.840 |
Why?
|
Conditioning, Classical | 7 | 2024 | 368 | 0.830 |
Why?
|
Prefrontal Cortex | 12 | 2023 | 2224 | 0.810 |
Why?
|
Mice, Inbred C57BL | 24 | 2024 | 22361 | 0.810 |
Why?
|
Motivation | 6 | 2017 | 2021 | 0.800 |
Why?
|
Dose-Response Relationship, Drug | 36 | 2021 | 10748 | 0.790 |
Why?
|
Mood Disorders | 8 | 2017 | 1129 | 0.780 |
Why?
|
Receptors, N-Methyl-D-Aspartate | 7 | 2017 | 903 | 0.780 |
Why?
|
Nerve Tissue Proteins | 6 | 2018 | 4401 | 0.770 |
Why?
|
Neurotransmitter Agents | 3 | 2015 | 661 | 0.760 |
Why?
|
Methylphenidate | 6 | 2024 | 480 | 0.750 |
Why?
|
Cycloserine | 3 | 2012 | 118 | 0.730 |
Why?
|
Social Behavior | 6 | 2019 | 1147 | 0.720 |
Why?
|
Nicotinic Agonists | 2 | 2020 | 265 | 0.720 |
Why?
|
Neurons | 20 | 2024 | 9517 | 0.720 |
Why?
|
Disease Models, Animal | 27 | 2020 | 18330 | 0.710 |
Why?
|
Brain-Derived Neurotrophic Factor | 1 | 2024 | 606 | 0.700 |
Why?
|
Self Administration | 14 | 2021 | 386 | 0.690 |
Why?
|
Sleep | 6 | 2025 | 4816 | 0.680 |
Why?
|
Diterpenes | 8 | 2007 | 169 | 0.680 |
Why?
|
Narcotics | 7 | 2013 | 332 | 0.660 |
Why?
|
Dopamine Agonists | 7 | 2020 | 346 | 0.660 |
Why?
|
Avoidance Learning | 6 | 2013 | 248 | 0.660 |
Why?
|
Pyrrolidines | 7 | 2019 | 339 | 0.650 |
Why?
|
Benzazepines | 5 | 2009 | 307 | 0.650 |
Why?
|
Nicotine | 4 | 2020 | 680 | 0.640 |
Why?
|
Depressive Disorder | 6 | 2017 | 3721 | 0.630 |
Why?
|
Bromocriptine | 5 | 2002 | 93 | 0.610 |
Why?
|
Psychotropic Drugs | 5 | 2009 | 881 | 0.610 |
Why?
|
Benzeneacetamides | 6 | 2013 | 36 | 0.590 |
Why?
|
Excitatory Amino Acid Antagonists | 6 | 2010 | 451 | 0.580 |
Why?
|
Toll-Like Receptor 7 | 1 | 2019 | 169 | 0.570 |
Why?
|
Neuropharmacology | 1 | 2017 | 19 | 0.570 |
Why?
|
Neuroimmunomodulation | 1 | 2019 | 186 | 0.570 |
Why?
|
3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer | 2 | 2019 | 19 | 0.560 |
Why?
|
Naltrexone | 9 | 2016 | 319 | 0.560 |
Why?
|
Microglia | 3 | 2024 | 1370 | 0.560 |
Why?
|
Telemetry | 1 | 2018 | 201 | 0.560 |
Why?
|
Brain Chemistry | 3 | 2005 | 951 | 0.560 |
Why?
|
Male | 127 | 2025 | 364203 | 0.550 |
Why?
|
Autistic Disorder | 2 | 2019 | 1239 | 0.550 |
Why?
|
Amphetamines | 2 | 2015 | 142 | 0.550 |
Why?
|
Depression | 12 | 2015 | 8234 | 0.530 |
Why?
|
Drug-Seeking Behavior | 2 | 2016 | 45 | 0.530 |
Why?
|
Reaction Time | 10 | 2021 | 2086 | 0.520 |
Why?
|
Rats, Long-Evans | 6 | 2024 | 380 | 0.520 |
Why?
|
Mice | 46 | 2024 | 81912 | 0.510 |
Why?
|
Receptors, GABA-A | 4 | 2021 | 624 | 0.500 |
Why?
|
Prenatal Exposure Delayed Effects | 5 | 2019 | 2538 | 0.490 |
Why?
|
Desipramine | 4 | 2008 | 183 | 0.490 |
Why?
|
Simplexvirus | 9 | 2015 | 805 | 0.480 |
Why?
|
Stress Disorders, Post-Traumatic | 7 | 2024 | 4629 | 0.470 |
Why?
|
Circadian Rhythm | 5 | 2025 | 2591 | 0.470 |
Why?
|
Tobacco Use Disorder | 1 | 2020 | 708 | 0.460 |
Why?
|
Mental Disorders | 7 | 2019 | 6873 | 0.450 |
Why?
|
Cocaine-Related Disorders | 2 | 2015 | 458 | 0.440 |
Why?
|
Immunity | 1 | 2019 | 1002 | 0.440 |
Why?
|
Neuronal Plasticity | 4 | 2018 | 1446 | 0.430 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2022 | 2568 | 0.430 |
Why?
|
Electric Stimulation | 15 | 2015 | 1736 | 0.430 |
Why?
|
Publishing | 1 | 2020 | 837 | 0.420 |
Why?
|
Gene Transfer Techniques | 10 | 2015 | 1207 | 0.420 |
Why?
|
Receptors, Dopamine D2 | 4 | 2021 | 471 | 0.420 |
Why?
|
Cytoskeletal Proteins | 1 | 2018 | 1326 | 0.420 |
Why?
|
Maze Learning | 6 | 2015 | 480 | 0.410 |
Why?
|
Compulsive Behavior | 1 | 2013 | 117 | 0.400 |
Why?
|
Microinjections | 8 | 2011 | 319 | 0.400 |
Why?
|
Maternal Exposure | 1 | 2019 | 1096 | 0.400 |
Why?
|
Hippocampus | 5 | 2024 | 3777 | 0.400 |
Why?
|
Genetic Vectors | 12 | 2015 | 3402 | 0.400 |
Why?
|
Locomotion | 5 | 2021 | 388 | 0.390 |
Why?
|
Antimetabolites | 1 | 2012 | 128 | 0.390 |
Why?
|
Salvia | 3 | 2008 | 13 | 0.380 |
Why?
|
Learning | 6 | 2017 | 1754 | 0.380 |
Why?
|
Phencyclidine | 4 | 1996 | 59 | 0.380 |
Why?
|
GABA-A Receptor Antagonists | 1 | 2011 | 59 | 0.370 |
Why?
|
Fetus | 1 | 2019 | 1878 | 0.370 |
Why?
|
Electroencephalography | 8 | 2025 | 6282 | 0.370 |
Why?
|
Depressive Disorder, Major | 4 | 2023 | 4813 | 0.370 |
Why?
|
Synaptic Transmission | 9 | 2018 | 1175 | 0.370 |
Why?
|
Inflammation | 3 | 2021 | 10869 | 0.370 |
Why?
|
Behavior, Addictive | 5 | 2012 | 429 | 0.360 |
Why?
|
Excitatory Amino Acid Agonists | 2 | 2012 | 142 | 0.360 |
Why?
|
Mental Health | 2 | 2022 | 3272 | 0.360 |
Why?
|
Frontal Lobe | 2 | 2013 | 1408 | 0.350 |
Why?
|
Models, Psychological | 1 | 2014 | 823 | 0.340 |
Why?
|
Intracellular Signaling Peptides and Proteins | 2 | 2014 | 2887 | 0.340 |
Why?
|
Corticosterone | 3 | 2024 | 301 | 0.340 |
Why?
|
Mammals | 3 | 2022 | 1135 | 0.340 |
Why?
|
Thalamus | 2 | 2013 | 1040 | 0.330 |
Why?
|
Drug Discovery | 2 | 2019 | 1068 | 0.330 |
Why?
|
Long-Term Potentiation | 4 | 2009 | 289 | 0.330 |
Why?
|
Executive Function | 2 | 2024 | 1396 | 0.330 |
Why?
|
Sex Characteristics | 2 | 2019 | 2647 | 0.330 |
Why?
|
Cannabis | 1 | 2015 | 447 | 0.320 |
Why?
|
Chromosomal Proteins, Non-Histone | 2 | 2024 | 724 | 0.320 |
Why?
|
Cyclic AMP-Dependent Protein Kinases | 2 | 2009 | 482 | 0.320 |
Why?
|
Hyperkinesis | 1 | 2009 | 88 | 0.320 |
Why?
|
Neurogenesis | 1 | 2015 | 863 | 0.310 |
Why?
|
Lovastatin | 1 | 2008 | 114 | 0.310 |
Why?
|
Neuropeptides | 1 | 2014 | 950 | 0.300 |
Why?
|
Cytidine | 2 | 2012 | 60 | 0.300 |
Why?
|
Paraventricular Hypothalamic Nucleus | 2 | 2024 | 121 | 0.300 |
Why?
|
Valproic Acid | 2 | 2012 | 444 | 0.300 |
Why?
|
Veterans | 1 | 2022 | 2666 | 0.300 |
Why?
|
Membrane Glycoproteins | 1 | 2019 | 3702 | 0.290 |
Why?
|
Raphe Nuclei | 1 | 2007 | 104 | 0.290 |
Why?
|
Fluoxetine | 2 | 2008 | 733 | 0.280 |
Why?
|
Psychomotor Performance | 4 | 2015 | 1886 | 0.280 |
Why?
|
Electroshock | 1 | 2007 | 120 | 0.280 |
Why?
|
Signal Transduction | 11 | 2024 | 23621 | 0.280 |
Why?
|
Lithium | 3 | 2007 | 600 | 0.280 |
Why?
|
Gene Expression Regulation | 14 | 2016 | 11923 | 0.280 |
Why?
|
Internet | 1 | 2019 | 3114 | 0.270 |
Why?
|
Anesthetics, Local | 2 | 2011 | 1005 | 0.270 |
Why?
|
Behavioral Research | 1 | 2007 | 52 | 0.270 |
Why?
|
Cannabinoids | 2 | 2022 | 174 | 0.270 |
Why?
|
Nomifensine | 2 | 1996 | 14 | 0.270 |
Why?
|
Analysis of Variance | 11 | 2012 | 6215 | 0.270 |
Why?
|
Immunity, Innate | 1 | 2019 | 3076 | 0.270 |
Why?
|
Cognition | 4 | 2024 | 7059 | 0.270 |
Why?
|
Affect | 3 | 2017 | 1494 | 0.260 |
Why?
|
Neuroglia | 2 | 2014 | 960 | 0.260 |
Why?
|
Anxiety | 4 | 2021 | 4670 | 0.260 |
Why?
|
Psychiatry | 1 | 2018 | 1715 | 0.260 |
Why?
|
Formaldehyde | 2 | 2020 | 360 | 0.250 |
Why?
|
Central Nervous System Diseases | 1 | 2010 | 518 | 0.250 |
Why?
|
Diltiazem | 1 | 2006 | 132 | 0.250 |
Why?
|
Time Factors | 23 | 2015 | 40154 | 0.250 |
Why?
|
Limbic System | 3 | 2006 | 418 | 0.250 |
Why?
|
Memory | 4 | 2024 | 2192 | 0.250 |
Why?
|
Autoimmune Diseases | 2 | 2014 | 2255 | 0.240 |
Why?
|
Mice, Transgenic | 8 | 2021 | 9551 | 0.240 |
Why?
|
Humans | 71 | 2024 | 767040 | 0.240 |
Why?
|
Uridine | 1 | 2005 | 135 | 0.240 |
Why?
|
Analgesics, Opioid | 8 | 2025 | 3837 | 0.230 |
Why?
|
Obsessive-Compulsive Disorder | 1 | 2013 | 1495 | 0.220 |
Why?
|
Tacrolimus Binding Proteins | 1 | 2024 | 199 | 0.220 |
Why?
|
Lipopolysaccharides | 3 | 2021 | 2217 | 0.220 |
Why?
|
Oxycodone | 1 | 2025 | 144 | 0.220 |
Why?
|
Leadership | 1 | 2013 | 1394 | 0.210 |
Why?
|
Choice Behavior | 2 | 2007 | 848 | 0.210 |
Why?
|
Electromagnetic Fields | 1 | 2005 | 290 | 0.210 |
Why?
|
Morphinans | 2 | 2013 | 27 | 0.210 |
Why?
|
Drug Interactions | 6 | 2011 | 1419 | 0.210 |
Why?
|
Receptors, Glucocorticoid | 1 | 2024 | 309 | 0.210 |
Why?
|
Calcium Channel Blockers | 1 | 2006 | 688 | 0.200 |
Why?
|
DNA, Circular | 1 | 2022 | 97 | 0.200 |
Why?
|
Neostriatum | 1 | 2003 | 231 | 0.200 |
Why?
|
Glutamates | 1 | 2003 | 384 | 0.200 |
Why?
|
Cytokines | 4 | 2024 | 7446 | 0.200 |
Why?
|
Gene Targeting | 1 | 2005 | 841 | 0.200 |
Why?
|
Guanidines | 2 | 2013 | 194 | 0.200 |
Why?
|
Epilepsy | 1 | 2017 | 3317 | 0.190 |
Why?
|
Hypokinesia | 1 | 2001 | 23 | 0.190 |
Why?
|
Hypothalamic Area, Lateral | 2 | 2011 | 108 | 0.190 |
Why?
|
Receptors, Serotonin | 1 | 2002 | 210 | 0.190 |
Why?
|
Dopamine Agents | 2 | 2021 | 186 | 0.190 |
Why?
|
Freezing Reaction, Cataleptic | 2 | 2015 | 40 | 0.190 |
Why?
|
Injections, Subcutaneous | 2 | 2020 | 685 | 0.190 |
Why?
|
Pandemics | 2 | 2022 | 8736 | 0.190 |
Why?
|
Pituitary-Adrenal System | 1 | 2024 | 555 | 0.190 |
Why?
|
Stress, Physiological | 1 | 2008 | 1407 | 0.190 |
Why?
|
Research Design | 1 | 2017 | 6210 | 0.190 |
Why?
|
Drug Synergism | 5 | 2008 | 1759 | 0.180 |
Why?
|
Electromyography | 2 | 2025 | 1398 | 0.180 |
Why?
|
Heterogeneous-Nuclear Ribonucleoproteins | 1 | 2021 | 69 | 0.180 |
Why?
|
Echo-Planar Imaging | 1 | 2005 | 648 | 0.180 |
Why?
|
Behavior | 1 | 2004 | 538 | 0.180 |
Why?
|
Gene Expression | 6 | 2019 | 7587 | 0.180 |
Why?
|
Ion Channels | 1 | 2005 | 1043 | 0.180 |
Why?
|
Fatty Acids, Omega-3 | 2 | 2012 | 1399 | 0.180 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 2 | 2014 | 616 | 0.180 |
Why?
|
Hypothalamo-Hypophyseal System | 1 | 2024 | 703 | 0.180 |
Why?
|
Transfection | 2 | 2005 | 5753 | 0.170 |
Why?
|
Antipsychotic Agents | 3 | 2009 | 3078 | 0.170 |
Why?
|
Infusion Pumps, Implantable | 1 | 2020 | 158 | 0.170 |
Why?
|
Rodentia | 1 | 2021 | 262 | 0.170 |
Why?
|
Opioid-Related Disorders | 2 | 2012 | 2188 | 0.160 |
Why?
|
Receptors, GABA | 1 | 2021 | 312 | 0.160 |
Why?
|
Kainic Acid | 3 | 2015 | 203 | 0.160 |
Why?
|
Benzamides | 2 | 2019 | 1376 | 0.160 |
Why?
|
Glutamic Acid | 4 | 2017 | 1182 | 0.160 |
Why?
|
RNA, Messenger | 6 | 2018 | 12793 | 0.160 |
Why?
|
Dietary Fats | 1 | 2007 | 2001 | 0.160 |
Why?
|
Scalp | 1 | 2022 | 390 | 0.160 |
Why?
|
Isoquinolines | 2 | 2008 | 349 | 0.160 |
Why?
|
Methamphetamine | 1 | 2021 | 167 | 0.160 |
Why?
|
Immobility Response, Tonic | 2 | 2011 | 13 | 0.160 |
Why?
|
Mice, Knockout | 8 | 2017 | 14476 | 0.160 |
Why?
|
Infusions, Intraventricular | 2 | 2015 | 31 | 0.160 |
Why?
|
Hypothalamus | 2 | 2014 | 1002 | 0.150 |
Why?
|
Evoked Potentials | 1 | 2024 | 1050 | 0.150 |
Why?
|
DNA, Viral | 1 | 2005 | 2201 | 0.150 |
Why?
|
Acetamides | 2 | 2012 | 259 | 0.150 |
Why?
|
Drug Administration Routes | 2 | 2011 | 152 | 0.150 |
Why?
|
CREB-Binding Protein | 2 | 2016 | 147 | 0.150 |
Why?
|
Ligands | 3 | 2013 | 3273 | 0.150 |
Why?
|
Injections, Intravenous | 1 | 2020 | 1377 | 0.150 |
Why?
|
Gender Identity | 2 | 2022 | 769 | 0.150 |
Why?
|
Search Engine | 1 | 2019 | 142 | 0.150 |
Why?
|
Light | 2 | 2020 | 1358 | 0.150 |
Why?
|
Excitatory Postsynaptic Potentials | 4 | 2012 | 369 | 0.140 |
Why?
|
Reinforcement Schedule | 3 | 2012 | 123 | 0.140 |
Why?
|
Sleep Deprivation | 1 | 2024 | 848 | 0.140 |
Why?
|
Poly I-C | 1 | 2017 | 110 | 0.140 |
Why?
|
Pregnancy | 7 | 2023 | 30238 | 0.140 |
Why?
|
Opioid Peptides | 1 | 2017 | 37 | 0.140 |
Why?
|
Herpesvirus 1, Human | 1 | 2003 | 743 | 0.140 |
Why?
|
Pain | 5 | 2014 | 5101 | 0.140 |
Why?
|
Schizophrenia | 2 | 2017 | 6977 | 0.140 |
Why?
|
Racemases and Epimerases | 1 | 2017 | 113 | 0.140 |
Why?
|
Animals, Newborn | 2 | 2017 | 2677 | 0.130 |
Why?
|
Receptors, Opioid, delta | 3 | 2013 | 48 | 0.130 |
Why?
|
Analgesics, Non-Narcotic | 1 | 2019 | 370 | 0.130 |
Why?
|
Brain Diseases | 1 | 2005 | 1551 | 0.130 |
Why?
|
Endpoint Determination | 1 | 2019 | 592 | 0.130 |
Why?
|
Dominance-Subordination | 1 | 2015 | 26 | 0.130 |
Why?
|
Autophagy | 1 | 2024 | 1347 | 0.130 |
Why?
|
Acoustic Stimulation | 1 | 2020 | 1253 | 0.130 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 1 | 2011 | 3724 | 0.130 |
Why?
|
Blotting, Western | 5 | 2008 | 5022 | 0.120 |
Why?
|
Benzodiazepines | 2 | 2012 | 1137 | 0.120 |
Why?
|
Dopamine Plasma Membrane Transport Proteins | 2 | 2015 | 409 | 0.120 |
Why?
|
Interferon Inducers | 1 | 2014 | 24 | 0.120 |
Why?
|
Benzhydryl Compounds | 1 | 2022 | 944 | 0.120 |
Why?
|
Female | 24 | 2024 | 396660 | 0.120 |
Why?
|
Seizures | 2 | 2008 | 2996 | 0.120 |
Why?
|
Salicylamides | 1 | 1994 | 31 | 0.120 |
Why?
|
Electrodes, Implanted | 4 | 2009 | 835 | 0.120 |
Why?
|
Freund's Adjuvant | 1 | 2014 | 144 | 0.120 |
Why?
|
Photic Stimulation | 3 | 2021 | 1989 | 0.120 |
Why?
|
Neuropsychological Tests | 3 | 2021 | 7121 | 0.110 |
Why?
|
Body Temperature | 1 | 2017 | 780 | 0.110 |
Why?
|
Down-Regulation | 1 | 2001 | 2931 | 0.110 |
Why?
|
Models, Neurological | 3 | 2010 | 1747 | 0.110 |
Why?
|
Excitatory Amino Acid Transporter 2 | 1 | 2015 | 88 | 0.110 |
Why?
|
Serotonin | 3 | 2007 | 1045 | 0.110 |
Why?
|
Nootropic Agents | 1 | 2015 | 159 | 0.110 |
Why?
|
Melatonin | 1 | 2019 | 670 | 0.110 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2008 | 3249 | 0.110 |
Why?
|
Astrocytes | 2 | 2012 | 1352 | 0.110 |
Why?
|
Psychological Tests | 1 | 2015 | 642 | 0.110 |
Why?
|
Neuralgia | 1 | 2020 | 619 | 0.110 |
Why?
|
Biophysics | 2 | 2011 | 376 | 0.100 |
Why?
|
gamma-Aminobutyric Acid | 3 | 2021 | 1139 | 0.100 |
Why?
|
Tetrazoles | 1 | 1999 | 923 | 0.100 |
Why?
|
Fibroblast Growth Factor 2 | 1 | 2015 | 590 | 0.100 |
Why?
|
Neural Inhibition | 1 | 2017 | 589 | 0.100 |
Why?
|
Disease Susceptibility | 1 | 2019 | 1791 | 0.100 |
Why?
|
Random Allocation | 1 | 2017 | 2394 | 0.100 |
Why?
|
Receptors, Neurotransmitter | 1 | 2013 | 171 | 0.100 |
Why?
|
Piperazines | 2 | 2008 | 2548 | 0.100 |
Why?
|
Injections, Intraventricular | 1 | 2012 | 227 | 0.100 |
Why?
|
Microdialysis | 2 | 2017 | 156 | 0.100 |
Why?
|
Diazepam | 2 | 2010 | 215 | 0.100 |
Why?
|
Point Mutation | 2 | 2012 | 1591 | 0.100 |
Why?
|
Clozapine | 3 | 2016 | 509 | 0.100 |
Why?
|
Mitogen-Activated Protein Kinase 8 | 1 | 2011 | 71 | 0.100 |
Why?
|
Marijuana Abuse | 1 | 2015 | 409 | 0.090 |
Why?
|
Cyclic AMP | 2 | 2009 | 1472 | 0.090 |
Why?
|
Arousal | 3 | 2022 | 1174 | 0.090 |
Why?
|
Phosphopyruvate Hydratase | 1 | 2011 | 128 | 0.090 |
Why?
|
Impulsive Behavior | 1 | 2014 | 345 | 0.090 |
Why?
|
Tyrosine 3-Monooxygenase | 3 | 2007 | 367 | 0.090 |
Why?
|
Cell Proliferation | 1 | 2007 | 10455 | 0.090 |
Why?
|
Phosphorylation | 3 | 2008 | 8310 | 0.090 |
Why?
|
Interpersonal Relations | 2 | 2017 | 1432 | 0.090 |
Why?
|
Inflammation Mediators | 1 | 2019 | 1889 | 0.090 |
Why?
|
Encephalitis | 1 | 2014 | 441 | 0.090 |
Why?
|
Implosive Therapy | 1 | 2012 | 127 | 0.090 |
Why?
|
Information Dissemination | 1 | 2019 | 1142 | 0.090 |
Why?
|
Amphetamine | 3 | 2009 | 222 | 0.090 |
Why?
|
Neural Pathways | 6 | 2023 | 3078 | 0.090 |
Why?
|
Triazines | 1 | 2012 | 311 | 0.090 |
Why?
|
Dependovirus | 1 | 2015 | 720 | 0.090 |
Why?
|
Sex Factors | 3 | 2021 | 10622 | 0.090 |
Why?
|
Catalepsy | 1 | 2009 | 31 | 0.090 |
Why?
|
Structure-Activity Relationship | 7 | 2011 | 3052 | 0.080 |
Why?
|
Child Development Disorders, Pervasive | 1 | 2015 | 597 | 0.080 |
Why?
|
Receptors, Glutamate | 1 | 2010 | 228 | 0.080 |
Why?
|
Rats, Inbred Strains | 3 | 2003 | 2078 | 0.080 |
Why?
|
Thionucleotides | 1 | 2009 | 107 | 0.080 |
Why?
|
Bipolar Disorder | 4 | 2012 | 5130 | 0.080 |
Why?
|
Brain Tissue Transplantation | 1 | 2009 | 81 | 0.080 |
Why?
|
Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2010 | 180 | 0.080 |
Why?
|
Haloperidol | 2 | 2009 | 394 | 0.080 |
Why?
|
Fetal Tissue Transplantation | 1 | 2009 | 139 | 0.080 |
Why?
|
TRPC Cation Channels | 1 | 2009 | 111 | 0.080 |
Why?
|
Injections, Intraperitoneal | 2 | 2012 | 411 | 0.080 |
Why?
|
Epinephrine | 1 | 2011 | 782 | 0.070 |
Why?
|
Child | 5 | 2023 | 80771 | 0.070 |
Why?
|
Animal Experimentation | 1 | 2008 | 46 | 0.070 |
Why?
|
Cognition Disorders | 1 | 2022 | 3968 | 0.070 |
Why?
|
HIV-1 | 1 | 2005 | 6951 | 0.070 |
Why?
|
Biogenic Monoamines | 1 | 2007 | 50 | 0.070 |
Why?
|
Chronic Disease | 2 | 2015 | 9362 | 0.070 |
Why?
|
Genes, fos | 1 | 2008 | 176 | 0.070 |
Why?
|
Biomedical Research | 2 | 2017 | 3464 | 0.070 |
Why?
|
Ethers | 1 | 2007 | 72 | 0.070 |
Why?
|
Synapses | 3 | 2013 | 1759 | 0.070 |
Why?
|
Furans | 1 | 2008 | 199 | 0.070 |
Why?
|
Association Learning | 2 | 2005 | 219 | 0.070 |
Why?
|
Resilience, Psychological | 1 | 2015 | 807 | 0.070 |
Why?
|
Alcohols | 1 | 2007 | 94 | 0.070 |
Why?
|
Serial Learning | 1 | 2007 | 41 | 0.070 |
Why?
|
Efferent Pathways | 1 | 2007 | 164 | 0.070 |
Why?
|
Euphoria | 1 | 2007 | 64 | 0.070 |
Why?
|
Cells, Cultured | 4 | 2008 | 18989 | 0.070 |
Why?
|
Prosencephalon | 1 | 2009 | 305 | 0.070 |
Why?
|
Mice, Inbred BALB C | 2 | 2013 | 6226 | 0.070 |
Why?
|
Transcriptional Activation | 1 | 2013 | 1751 | 0.070 |
Why?
|
GTP Cyclohydrolase | 1 | 2006 | 46 | 0.070 |
Why?
|
Isoenzymes | 1 | 2011 | 1688 | 0.070 |
Why?
|
Bromodeoxyuridine | 1 | 2007 | 310 | 0.070 |
Why?
|
Species Specificity | 3 | 2024 | 2412 | 0.070 |
Why?
|
Dose-Response Relationship, Radiation | 2 | 2006 | 876 | 0.070 |
Why?
|
Dopamine Antagonists | 2 | 2020 | 279 | 0.070 |
Why?
|
Wakefulness | 2 | 2025 | 1282 | 0.070 |
Why?
|
Receptors, Dopamine | 1 | 2007 | 291 | 0.070 |
Why?
|
Disease | 1 | 2011 | 675 | 0.070 |
Why?
|
Transgenes | 2 | 2001 | 1014 | 0.060 |
Why?
|
Depression, Chemical | 1 | 2005 | 186 | 0.060 |
Why?
|
Adult | 10 | 2024 | 223317 | 0.060 |
Why?
|
Neurobiology | 1 | 2007 | 135 | 0.060 |
Why?
|
Antidepressive Agents, Second-Generation | 2 | 2007 | 491 | 0.060 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2017 | 2183 | 0.060 |
Why?
|
Models, Animal | 2 | 2020 | 2121 | 0.060 |
Why?
|
Terrorism | 1 | 2008 | 211 | 0.060 |
Why?
|
Tegmentum Mesencephali | 2 | 1999 | 59 | 0.060 |
Why?
|
Anti-Inflammatory Agents | 1 | 2014 | 1804 | 0.060 |
Why?
|
Pain, Intractable | 1 | 2006 | 132 | 0.060 |
Why?
|
Plant Leaves | 1 | 2005 | 153 | 0.060 |
Why?
|
T-Lymphocytes | 1 | 2022 | 10254 | 0.060 |
Why?
|
Acute Disease | 1 | 2015 | 7236 | 0.060 |
Why?
|
Social Dominance | 1 | 2024 | 39 | 0.060 |
Why?
|
Calcium Channels, L-Type | 1 | 2006 | 243 | 0.060 |
Why?
|
Binding, Competitive | 1 | 2005 | 1141 | 0.060 |
Why?
|
Basal Ganglia | 1 | 2007 | 549 | 0.060 |
Why?
|
Drug Design | 1 | 2009 | 1045 | 0.060 |
Why?
|
Gonadal Hormones | 1 | 2023 | 29 | 0.060 |
Why?
|
Protein Binding | 2 | 2013 | 9327 | 0.060 |
Why?
|
Colchicine | 1 | 2005 | 256 | 0.060 |
Why?
|
Proteoglycans | 1 | 2007 | 807 | 0.050 |
Why?
|
Extracellular Space | 1 | 2005 | 563 | 0.050 |
Why?
|
Gout Suppressants | 1 | 2005 | 176 | 0.050 |
Why?
|
Physical Stimulation | 1 | 2005 | 514 | 0.050 |
Why?
|
Research Personnel | 1 | 2008 | 589 | 0.050 |
Why?
|
Receptor, Serotonin, 5-HT1B | 1 | 2002 | 36 | 0.050 |
Why?
|
Memory Disorders | 1 | 2010 | 1193 | 0.050 |
Why?
|
Antidepressive Agents, Tricyclic | 1 | 2005 | 429 | 0.050 |
Why?
|
Cell Count | 1 | 2007 | 1825 | 0.050 |
Why?
|
Lac Operon | 1 | 2003 | 237 | 0.050 |
Why?
|
Immobilization | 1 | 2003 | 229 | 0.050 |
Why?
|
PC12 Cells | 1 | 2003 | 317 | 0.050 |
Why?
|
Carbon | 1 | 2006 | 672 | 0.050 |
Why?
|
Molecular Conformation | 3 | 2011 | 540 | 0.050 |
Why?
|
Pain Threshold | 1 | 2006 | 607 | 0.050 |
Why?
|
Alzheimer Disease | 1 | 2024 | 8717 | 0.050 |
Why?
|
Drug Evaluation, Preclinical | 3 | 2019 | 1331 | 0.050 |
Why?
|
Cytidine Diphosphate Choline | 1 | 2002 | 29 | 0.050 |
Why?
|
Anticonvulsants | 1 | 2012 | 1921 | 0.050 |
Why?
|
Entorhinal Cortex | 1 | 2024 | 285 | 0.050 |
Why?
|
Drug Implants | 1 | 2003 | 230 | 0.050 |
Why?
|
Neurites | 1 | 2024 | 389 | 0.050 |
Why?
|
Drug Combinations | 1 | 2008 | 2086 | 0.050 |
Why?
|
Molecular Sequence Data | 2 | 2013 | 17608 | 0.050 |
Why?
|
Cerebral Cortex | 2 | 2011 | 5754 | 0.050 |
Why?
|
Receptors, Adrenergic | 1 | 2001 | 155 | 0.050 |
Why?
|
Antigens | 1 | 2007 | 1442 | 0.050 |
Why?
|
Amino Acid Sequence | 1 | 2013 | 13411 | 0.050 |
Why?
|
Kinetics | 2 | 2013 | 6287 | 0.050 |
Why?
|
Peptides | 1 | 2013 | 4348 | 0.040 |
Why?
|
Lighting | 1 | 2003 | 210 | 0.040 |
Why?
|
Rats, Wistar | 3 | 2017 | 1885 | 0.040 |
Why?
|
Sleep Stages | 1 | 2025 | 705 | 0.040 |
Why?
|
Patch-Clamp Techniques | 2 | 2017 | 924 | 0.040 |
Why?
|
Embryonic Stem Cells | 1 | 2007 | 1244 | 0.040 |
Why?
|
Serine | 2 | 2017 | 828 | 0.040 |
Why?
|
Nerve Net | 1 | 2012 | 2307 | 0.040 |
Why?
|
Homeodomain Proteins | 1 | 2009 | 2429 | 0.040 |
Why?
|
Equipment and Supplies | 1 | 2003 | 272 | 0.040 |
Why?
|
Comorbidity | 2 | 2017 | 10582 | 0.040 |
Why?
|
Aging | 3 | 2004 | 8729 | 0.040 |
Why?
|
Drug Therapy, Combination | 2 | 2012 | 6310 | 0.040 |
Why?
|
Presynaptic Terminals | 1 | 2002 | 299 | 0.040 |
Why?
|
Immunoenzyme Techniques | 1 | 2003 | 1697 | 0.040 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 4572 | 0.040 |
Why?
|
CHO Cells | 3 | 2006 | 1376 | 0.040 |
Why?
|
Stem Cell Transplantation | 1 | 2007 | 1596 | 0.040 |
Why?
|
Adaptation, Physiological | 2 | 2006 | 1312 | 0.040 |
Why?
|
Delayed-Action Preparations | 1 | 2003 | 965 | 0.040 |
Why?
|
Receptors, Metabotropic Glutamate | 2 | 2011 | 188 | 0.040 |
Why?
|
Inflammasomes | 1 | 2024 | 540 | 0.040 |
Why?
|
Genes, Dominant | 1 | 2001 | 855 | 0.040 |
Why?
|
Sleep, REM | 1 | 2022 | 593 | 0.040 |
Why?
|
Evoked Potentials, Visual | 1 | 2021 | 417 | 0.040 |
Why?
|
Biological Transport | 2 | 2013 | 2084 | 0.040 |
Why?
|
Feeding Behavior | 2 | 2008 | 3207 | 0.040 |
Why?
|
Cricetinae | 3 | 2006 | 2415 | 0.040 |
Why?
|
Drug Delivery Systems | 1 | 2009 | 2212 | 0.040 |
Why?
|
Neurotensin | 1 | 2018 | 59 | 0.040 |
Why?
|
Tachykinins | 1 | 2018 | 78 | 0.040 |
Why?
|
Protein Kinase C-delta | 1 | 2018 | 115 | 0.040 |
Why?
|
Severity of Illness Index | 1 | 2015 | 15925 | 0.040 |
Why?
|
Trans-Activators | 1 | 2007 | 2856 | 0.040 |
Why?
|
Nerve Growth Factors | 1 | 2000 | 564 | 0.030 |
Why?
|
Neurosecretory Systems | 1 | 1998 | 223 | 0.030 |
Why?
|
Adrenergic alpha-2 Receptor Antagonists | 1 | 2016 | 18 | 0.030 |
Why?
|
Clinical Trials as Topic | 1 | 2013 | 8048 | 0.030 |
Why?
|
Yohimbine | 1 | 2016 | 63 | 0.030 |
Why?
|
Enzyme Inhibitors | 2 | 2006 | 3726 | 0.030 |
Why?
|
Lactic Acid | 2 | 2013 | 1139 | 0.030 |
Why?
|
Somatostatin | 1 | 2018 | 458 | 0.030 |
Why?
|
Pain Measurement | 2 | 2009 | 3584 | 0.030 |
Why?
|
Models, Molecular | 1 | 2005 | 5388 | 0.030 |
Why?
|
Treatment Outcome | 5 | 2015 | 65295 | 0.030 |
Why?
|
Hierarchy, Social | 1 | 2014 | 24 | 0.030 |
Why?
|
Recurrence | 1 | 2007 | 8504 | 0.030 |
Why?
|
Raclopride | 1 | 1994 | 98 | 0.030 |
Why?
|
Up-Regulation | 2 | 2007 | 4143 | 0.030 |
Why?
|
Attitude of Health Personnel | 1 | 2008 | 3928 | 0.030 |
Why?
|
Ketoprofen | 1 | 2013 | 8 | 0.030 |
Why?
|
Alcoholism | 1 | 2005 | 1980 | 0.030 |
Why?
|
Microscopy, Confocal | 1 | 2000 | 1969 | 0.030 |
Why?
|
Glucocorticoids | 1 | 2023 | 2163 | 0.030 |
Why?
|
Double-Blind Method | 2 | 2022 | 12451 | 0.030 |
Why?
|
Protein Precursors | 1 | 2018 | 1134 | 0.030 |
Why?
|
Exploratory Behavior | 2 | 2009 | 271 | 0.030 |
Why?
|
Norepinephrine Plasma Membrane Transport Proteins | 1 | 2013 | 66 | 0.030 |
Why?
|
Receptors, Adrenergic, alpha | 1 | 2013 | 146 | 0.030 |
Why?
|
Brain Mapping | 2 | 2007 | 6597 | 0.030 |
Why?
|
Enkephalins | 1 | 1993 | 139 | 0.030 |
Why?
|
Scopolamine Derivatives | 1 | 1993 | 23 | 0.030 |
Why?
|
2-Amino-5-phosphonovalerate | 1 | 2013 | 57 | 0.030 |
Why?
|
Neuroprotective Agents | 1 | 2000 | 956 | 0.030 |
Why?
|
Interneurons | 1 | 2018 | 592 | 0.030 |
Why?
|
Galantamine | 1 | 1993 | 33 | 0.030 |
Why?
|
Stereotaxic Techniques | 1 | 2015 | 551 | 0.030 |
Why?
|
Microdissection | 1 | 2013 | 150 | 0.030 |
Why?
|
Caco-2 Cells | 1 | 2013 | 364 | 0.030 |
Why?
|
Protein Kinase Inhibitors | 1 | 2009 | 5693 | 0.030 |
Why?
|
Molecular Structure | 2 | 2007 | 1882 | 0.030 |
Why?
|
GABA Agents | 1 | 2012 | 41 | 0.030 |
Why?
|
LLC-PK1 Cells | 1 | 2012 | 125 | 0.030 |
Why?
|
Calcium | 2 | 2013 | 5792 | 0.020 |
Why?
|
Receptors, Opioid, mu | 1 | 2013 | 167 | 0.020 |
Why?
|
Gene Knockdown Techniques | 1 | 2017 | 1604 | 0.020 |
Why?
|
Tissue Distribution | 1 | 2016 | 2275 | 0.020 |
Why?
|
Allosteric Regulation | 1 | 2013 | 424 | 0.020 |
Why?
|
Tissue Culture Techniques | 1 | 2013 | 287 | 0.020 |
Why?
|
Inositol 1,4,5-Trisphosphate | 1 | 2011 | 110 | 0.020 |
Why?
|
Sucrose | 1 | 2012 | 156 | 0.020 |
Why?
|
Receptors, Kainic Acid | 1 | 2011 | 91 | 0.020 |
Why?
|
Sensitivity and Specificity | 1 | 2007 | 14672 | 0.020 |
Why?
|
Adrenergic Agents | 1 | 2011 | 72 | 0.020 |
Why?
|
Age Factors | 2 | 2006 | 18401 | 0.020 |
Why?
|
Hormones | 1 | 2015 | 865 | 0.020 |
Why?
|
Drug Tolerance | 1 | 1993 | 365 | 0.020 |
Why?
|
Chlordiazepoxide | 1 | 2010 | 42 | 0.020 |
Why?
|
Hydrophobic and Hydrophilic Interactions | 1 | 2012 | 391 | 0.020 |
Why?
|
Norepinephrine | 1 | 2013 | 898 | 0.020 |
Why?
|
Hindlimb Suspension | 1 | 2011 | 77 | 0.020 |
Why?
|
Alprazolam | 1 | 2010 | 103 | 0.020 |
Why?
|
Diet | 1 | 2008 | 8089 | 0.020 |
Why?
|
GABA Modulators | 1 | 2010 | 108 | 0.020 |
Why?
|
Hyperalgesia | 1 | 2014 | 527 | 0.020 |
Why?
|
Mitochondria | 1 | 2023 | 3678 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2001 | 5796 | 0.020 |
Why?
|
Permeability | 1 | 2012 | 721 | 0.020 |
Why?
|
Transcription Factors | 1 | 2009 | 12158 | 0.020 |
Why?
|
Apomorphine | 1 | 2009 | 148 | 0.020 |
Why?
|
Aphakia | 1 | 2009 | 26 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2014 | 1244 | 0.020 |
Why?
|
Receptors, Opioid | 1 | 1989 | 145 | 0.020 |
Why?
|
Threonine | 1 | 2010 | 272 | 0.020 |
Why?
|
Administration, Oral | 2 | 2007 | 4026 | 0.020 |
Why?
|
Protein Subunits | 1 | 2012 | 940 | 0.020 |
Why?
|
Food Preferences | 1 | 2012 | 397 | 0.020 |
Why?
|
Animal Rights | 1 | 2008 | 10 | 0.020 |
Why?
|
Aromatic-L-Amino-Acid Decarboxylases | 1 | 2007 | 27 | 0.020 |
Why?
|
Brain Waves | 1 | 2012 | 416 | 0.020 |
Why?
|
Microsomes, Liver | 1 | 2007 | 174 | 0.020 |
Why?
|
Rats, Inbred F344 | 2 | 1999 | 820 | 0.020 |
Why?
|
Aspartic Acid | 1 | 2010 | 575 | 0.020 |
Why?
|
Radioligand Assay | 1 | 2007 | 365 | 0.020 |
Why?
|
Gene Expression Profiling | 1 | 2023 | 9532 | 0.020 |
Why?
|
Calcium Signaling | 1 | 2011 | 736 | 0.020 |
Why?
|
CLOCK Proteins | 1 | 2007 | 87 | 0.020 |
Why?
|
Crime | 1 | 2008 | 206 | 0.020 |
Why?
|
Ethics, Research | 1 | 2008 | 178 | 0.020 |
Why?
|
6-Cyano-7-nitroquinoxaline-2,3-dione | 1 | 2006 | 55 | 0.020 |
Why?
|
Treatment Failure | 1 | 2012 | 2658 | 0.020 |
Why?
|
Muscimol | 1 | 2006 | 70 | 0.020 |
Why?
|
Quinoxalines | 1 | 2008 | 297 | 0.020 |
Why?
|
Alcohol Oxidoreductases | 1 | 2006 | 164 | 0.020 |
Why?
|
Guanosine 5'-O-(3-Thiotriphosphate) | 1 | 2005 | 87 | 0.020 |
Why?
|
Sirolimus | 1 | 2013 | 1539 | 0.020 |
Why?
|
Drug Administration Schedule | 2 | 2007 | 4855 | 0.020 |
Why?
|
GABA Agonists | 1 | 2006 | 106 | 0.020 |
Why?
|
Primates | 1 | 2008 | 519 | 0.020 |
Why?
|
Enzyme Activation | 1 | 2011 | 3587 | 0.020 |
Why?
|
Lithium Compounds | 1 | 2007 | 226 | 0.020 |
Why?
|
Esters | 1 | 2006 | 212 | 0.020 |
Why?
|
Immunohistochemistry | 3 | 2007 | 11063 | 0.020 |
Why?
|
Staining and Labeling | 1 | 2009 | 1076 | 0.020 |
Why?
|
Behavioral Symptoms | 1 | 2007 | 188 | 0.020 |
Why?
|
Glycogen Synthase Kinase 3 | 1 | 2007 | 414 | 0.020 |
Why?
|
Methylation | 1 | 2007 | 1076 | 0.010 |
Why?
|
Inhibitory Concentration 50 | 1 | 2005 | 464 | 0.010 |
Why?
|
Citalopram | 1 | 2007 | 402 | 0.010 |
Why?
|
Amines | 1 | 2006 | 280 | 0.010 |
Why?
|
Cricetulus | 1 | 2006 | 810 | 0.010 |
Why?
|
Auditory Perception | 1 | 2009 | 586 | 0.010 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2013 | 2061 | 0.010 |
Why?
|
Young Adult | 2 | 2024 | 59980 | 0.010 |
Why?
|
Body Weight | 1 | 2014 | 4627 | 0.010 |
Why?
|
Amides | 1 | 2006 | 451 | 0.010 |
Why?
|
Cell Line | 2 | 2011 | 15567 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2021 | 20169 | 0.010 |
Why?
|
Mutagenesis | 1 | 2007 | 1227 | 0.010 |
Why?
|
Catheterization | 1 | 2008 | 1430 | 0.010 |
Why?
|
Swine | 1 | 2012 | 5987 | 0.010 |
Why?
|
Plant Extracts | 1 | 2005 | 496 | 0.010 |
Why?
|
Membrane Transport Proteins | 1 | 2007 | 1029 | 0.010 |
Why?
|
Dopamine beta-Hydroxylase | 1 | 2001 | 74 | 0.010 |
Why?
|
Hypnotics and Sedatives | 1 | 2009 | 1193 | 0.010 |
Why?
|
Visual Perception | 1 | 2009 | 1392 | 0.010 |
Why?
|
beta-Galactosidase | 1 | 2001 | 573 | 0.010 |
Why?
|
Haplotypes | 1 | 2006 | 2722 | 0.010 |
Why?
|
Glial Cell Line-Derived Neurotrophic Factor | 1 | 2000 | 66 | 0.010 |
Why?
|
Receptors, G-Protein-Coupled | 1 | 2007 | 1244 | 0.010 |
Why?
|
Electrophysiology | 1 | 2002 | 1263 | 0.010 |
Why?
|
Mice, Inbred A | 1 | 1998 | 245 | 0.010 |
Why?
|
Putamen | 1 | 1999 | 288 | 0.010 |
Why?
|
Caudate Nucleus | 1 | 1999 | 388 | 0.010 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2006 | 3797 | 0.010 |
Why?
|
Genes, Reporter | 1 | 2001 | 1526 | 0.010 |
Why?
|
Adenoviridae | 1 | 2001 | 1092 | 0.010 |
Why?
|
Rats, Inbred Lew | 1 | 1998 | 1168 | 0.010 |
Why?
|
Plasmids | 1 | 2001 | 2268 | 0.010 |
Why?
|
RNA | 1 | 2006 | 2715 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2023 | 36582 | 0.010 |
Why?
|
Quantitative Trait, Heritable | 1 | 1998 | 539 | 0.010 |
Why?
|
HeLa Cells | 1 | 2001 | 3073 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2011 | 17097 | 0.010 |
Why?
|
Microscopy, Fluorescence | 1 | 2001 | 2628 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2013 | 7469 | 0.010 |
Why?
|
GTP-Binding Proteins | 1 | 1998 | 946 | 0.010 |
Why?
|
Enkephalin, D-Penicillamine (2,5)- | 1 | 1993 | 2 | 0.010 |
Why?
|
3,4-Dihydroxyphenylacetic Acid | 1 | 1993 | 60 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 2001 | 6106 | 0.010 |
Why?
|
Recombination, Genetic | 1 | 1998 | 1524 | 0.010 |
Why?
|
Basal Metabolism | 1 | 1993 | 163 | 0.010 |
Why?
|
Diffusion | 1 | 1993 | 810 | 0.010 |
Why?
|
Base Sequence | 1 | 2001 | 12414 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2007 | 11657 | 0.010 |
Why?
|
Space Perception | 1 | 1993 | 468 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 2001 | 7611 | 0.000 |
Why?
|
Adolescent | 1 | 2015 | 89046 | 0.000 |
Why?
|
Social Environment | 1 | 1989 | 1012 | 0.000 |
Why?
|
Mutation | 1 | 2007 | 30211 | 0.000 |
Why?
|
Prospective Studies | 1 | 2006 | 54886 | 0.000 |
Why?
|
United States | 1 | 2008 | 72971 | 0.000 |
Why?
|
Dementia | 1 | 1993 | 2741 | 0.000 |
Why?
|
Middle Aged | 1 | 2012 | 223233 | 0.000 |
Why?
|